Positive outcomes for apalutamide in the treatment of mHSPC

According to a media release issued late yesterday by Johnson & Johnson, the combination of apalutamide (Erleada) + androgen deprivation therapy (ADT) has met the primary study endpoints in the so-called TITAN trial. … READ MORE …

Is time to biochemical failure a good surrogate endpoint for overall survival?

For many years researchers have been trying to identify so-called “surrogate” endpoints that can be used to predict overall and prostate cancer-specific survival with high accuracy. … READ MORE …

Age-related risks of radical prostatectomy

It will hardly come as a surprise to most prostate cancer support group leaders and other prostate cancer advocates that there is a strong association between patient age and risk for side effects of radical prostatectomy. … READ MORE …

Can MRI data improve decision-making about the need for a biopsy?

Last week we noted that adding MRI data to the Partin tables and to the Kattan/MSKCC nomograms did not seem to improve the accuracy of prognosis of outcomes after radical prostatectomy. … READ MORE …

ADT + enzalutamide in mHSPC … outcome of the ARCHES trial

Pfizer and Astellas have, this morning, announced that the addition of enzalutamide to standard androgen deprivation (ADT) has led to improved outcomes in men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …

Pembrolizumab in treatment of advanced prostate cancer

We finally have some published data — albeit not a lot — on the use of one of the PD-1 inhibitors (pembrolizumab, also known as Keytruda) in the treatment of late-stage prostate cancer. … READ MORE …

Statins and the treatment of mCRPC with chemotherapy

A report on the UroToday web site has addressed a presentation given this week at the ESMO 2018 Congress in Munich, Germany, that is relevant to the potential value of taking a statin while you are being treated for very late stage prostate cancer. … READ MORE …